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Abstract
Atrial fibrillation (AF) is one of major problems of the contemporary cardiology. Ischaemic stroke is a common complication of the AF, and 
effective prophylaxis requires treatment with oral anticoagulants.  The purpose of this current review article is to provide an overview of the 
various stroke and bleeding risk assessment scores that help decision making with respect to thromboprophylaxis.   
Particular focus is made on the currently guideline-recommended stroke and bleeding risk scores, such as CHA2DS2-VASc (congestive 
heart failure or left ventricular dysfunction, hypertension, age ≥75, diabetes, stroke, vascular disease, age 65–74 and sex category [female]) 
and HAS-BLED (uncontrolled hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international 
normalized ratio, elderly [e.g. age >65, frail condition], drugs [e.g. aspirin, nonsteroidal anti-inflammatory drugs]/excessive alcohol) is made. 
Future directions for improvement of predictive ability of risk assessment with clinical factors and biomarkers are also discussed.
Introduction
Atrial fibrillation (AF) is one of commonest cardiovascular 
conditions we deal with. The prevalence of AF is approximatel 
1-2% in the general population.1 In a recent study population-bases 
study, the prevalence of AF was 3.2% in subjects age ≥20 years old.2 
Ischaemic stroke is one of the major complications of AF, which has 
a high mortality and disability when strokes occur in association with 
AF.3
Effective thromboprophylaxis requires treatment with oral 
anticoagulants.  Currently, two options, either the vitamin K 
antagonists (VKAs, eg. warfarin), or the non-VKA (previously 
referred to as novel or new) oral anticoagulants such as the oral 
direct thrombin inhibitor (dabigatran) or the oral factor Xa blockers 
[rivaroxaban, apixaban, edoxaban]).4 Whilst effective in reducing 
stroke and all cause mortality, oral anticoagulants result in an elevated 
risk of bleeding that can sometimes be life-threatening.5  Intracranial 
bleeding is the most devastating example of major bleeding events, 
but is up to 9 times less common than ischaemic strokes.2 Thus, the 
net clinical benefit of oral anticoagulation (balancing ischaemic 
stroke versus major bleeding) was is generally positive in AF with 
one or more stroke risk factors.6,7
The purpose of the current review article is to provide an overview 
of the various stroke and bleeding risk assessment tools. These are 
validated instruments which provide help in making decisions with 
respect to antithrombotic prophylaxis.   Particular focus will be on the 
currently recommended risk scores as CHA2DS2-VASc (congestive 
heart failure or left ventricular dysfunction, hypertension, age ≥75, 
diabetes, stroke/transient ischaemic attack [TIA], vascular disease, 
age 65–74 and sex category [female]), and HAS-BLED (uncontrolled 
hypertension, abnormal renal/liver function, stroke, bleeding history 
or predisposition, labile INR, elderly [e.g. age >65, frail condition], 
drugs [e.g., antiplatelet, nonsteroidal anti-inflammatory drugs]/
excessive alcohol). Future directions for improvement of predictive 
ability of risk assessment with clinical factors and biomarkers are also 
discussed.
Stroke Risk Assessment In Atrial Fibrillation
There are various published stroke risk stratification schemes, 
amongst which the CHADS2 score (congestive heart failure, 
hypertension, age ≥75, diabetes mellitus, stroke/TIA) and the 
CHA2DS2-VASc scores are most commonly used, having been 
validated and compared in numerous clinical trial populationss and 
‘real world’ cohorts.8,9
Previous stroke risk scores from older guidelines10-12 as well as the 
Framingham score,13 and ‘classical’ CHADS2 score14 have all focused 
on stroke risk assessment by (artificially) categorizing patients into 
three risk categories: low, moderate and high.  This was explained 
from the practical point of view, because thromboprophylaxis was 
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incidence of stroke.21  Furthermore, this aspirin was ineffective with 
increasing age.22
 In the ‘real world’ Danish nationwide cohort study, significant 
reductions of stroke risk with warfarin in comparison with aspirin, 
as well as similarity of bleeding risk with warfarin and aspirin were 
confirmed.7 Also, the significant value of warfarin was seen in patients 
with one stroke risk factor eg. CHADS2 score=1.23,24
Clearly things may be improving, over the last decade, with 
about 80% of AF patients with ≥1 stroke risk factors now being 
prescribed oral anticoagulants, although the rate of administration 
of antiplatelet agents still remains high, particularly in patients with 
elevated bleeding risk.25
Basically, various stroke risk stratification schemes are based on 
various permutations of stroke risk predictors in AF.  These include 
such independent risk factors as stroke/TIA, increasing age, history 
of hypertension, and diabetes mellitus. The predictive role of the 
female gender, heart failure, and vascular disease are supported by 
more recently available data.26,27
The CHADS2 ScoreThe CHADS2 score is one of the simplest risk stratification schemes, 
and was derived by the combination of 2 stroke rirsk classification 
schemes from non-anticoagulated arms of AF Investigators (AFI) 
and Stroke Prevention and Atrial fibrillation (SPAF) datasets, 
including: prior cerebral ischemia, history of hypertension, diabetes 
mellitus, congestive heart failure and age ≥75 years.14 Two points 
were assigned to a history of prior cerebral ischemia and 1 point 
was assigned for the presence of other risk factors.14 One validation 
of CHADS2 score was performed on an independent sample of 
National Registry of Atrial Fibrillation. participants and was highly 
correlated with the stroke rate: 1.9 (95% CI 1.2-3.0) for a score of 0; 
2.8 (95% CI 2.0-3.8) for 1; 4.0 (95% CI 3.1-5.1) for 2; 5.9 (95% CI 
4.6-7.3) for 3; 8.5 (95% CI 6.3-11.1) for 4; 12.5 (95% CI 8.2-17.5) 
for 5; and 18.2 (95% CI 10.5-27.4) for 6.14
The CHADS2 score was further tested in 2580 participants 
with nonvalvular AF taking aspirin from several randomized trials 
(Atrial fibrillation, Aspirin, Anticoagulation I Study [AFASAK-1], 
AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention 
of Arterial Thromboembolism in patients with nonrheumatic AF 
in primary care study and SPAF III) in comparison with the AFI, 
SPAF, ACCP and Framingham stratification criteria.28  In this study. 
the CHADS2 scheme identified successfully and better than other 
stratification schemes primary prevention patients who were at high-
risk of stroke as well as low risk patients were identified equally by 
all schemes.28 However, in the ATRIA (AnTicoagulation and Risk 
Factors In Atrial Fibrillation) cohort of 13559 adults with AF and 
685 validated thromboembolic events during median follow-up of 
6.0 years the CHADS2 score was not superior to other stratification 
schemes (AFI, SPAF, Framingham, 7th ACCP) in prediction of 
stroke or other thromboembolic events, which all had c-statistics 
ranging from 0.56 to 0.62.29 
There was a concern as for appropriateness of stratification with 
the CHADS2 scheme, particularly in its ‘classical’ interpretation.  As 
many as >60% AF patients could be categorized into the ‘moderate 
or intermediate risk’ stratum with the CHADS2 scheme, where 
guidelines recommended ‘warfarin or aspirin’ which made decision-
making difficult.29  The most obvious example is a history of stroke or 
TIA in the absence of other CHADS2 risk factor, where the CHADS2 
down to an inconvenient drug, warfarin – and if not, aspirin.   Thus, 
old guidelines had focused on the identification of ‘high risk’ patients 
who could be targeted for warfarin.
First, such artificial categorization leads to more crude estimation 
and overall reduced discriminative ability of the risk stratification 
tools, that is, potential misclassification of patient’s stroke risk and 
following inappropriate treatment.15-17 Second, risk assessment 
schemes are strongly dependent on the cohorts, from which they were 
derived and validated.  These cohorts, particularly those from older 
clinical trials and epidemiological studies, can be extensively variable 
in terms of documentation of stroke risk factors and differences 
in definitions of stroke risk factors between cohorts.  For example, 
‘hypertension’ may stand for ‘history of hypertension’ [irrespectively of 
stage or clinical course] or ‘uncontrolled hypertension’ [systolic blood 
pressure >160 mmHg].8,9  Third, freedom to choose between drugs 
for antithrombotic prophylaxis is likely to be cause of undertreatment 
of patients with AF.  Indeed, aspirin was erroneously perceived to be 
safer with lower rates of bleeding, and sufficiently effective to prevent 
thromboembolic events; also, aspirin more convenient as it did not 
require regular monitoring of the quality of anticoagulation.18,19
In the EuroHeart survey, patients with AF were often prescribed 
oral anticoagulation irrespectively of stroke risk both in low (up to 
half of patients) and high risk strata, thus underscoring their low 
directive impact on the decision-making when prescribing oral 
anticoagulants.20  Anticoagulation was also more commonly used in 
such circumstances as the first episode of AF, absence of significant 
comorbidity, and the availability of facilities for regular INR control. 
On the contrary, well known components of the CHADS2 score 
(history of stroke/TIA, hypertension, age >75 years) were associated 
with the administration of aspirin.20  Moreover, separate risk 
categories overlapped when different risk stratification schemes 
were applied.20  Indeed, the relative complexity of the compared 
risk assessment tools (apart from the CHADS2) and inconsistence 
between guidelines were acknowledged as one of the reason for such 
‘unexpected’ results.20  
We now recognize that aspirin was is neither effective nor safe for 
stroke prevention. In the meta-analysis of antithrombotic therapy in 
patients with non-valvular A, warfarin was superior to antiplatelet 
therapy (39% relative risk reduction, 95% confidence interval [CI] 
22-52%) and aspirin monotherapy did not significantly reduce the 
Table 1: Stroke and bleeding risk stratification with the CHA2DS2-VASc
30  
and HAS-BLED56  scores
CHA2DS2-VASc Score HAS-BLED Score
Congestive heart failure/LV 
dysfunction
1 Hypertension (systolic blood pressure 
>160 mmHg)
1
Hypertension 1 Abnormal renal or liver function 1 or 2
Age ≥75 years 2 Stroke 1
Diabetes mellitus 1 Bleeding tendency or predisposition 1
Stroke/TIA/TE 2 Labile INRs (if on warfarin) 1
Vascular disease (prior MI, PAD, or 
aortic plaque)
1 Age (e.g., >65, frail condition) 1
Aged 65–74 years 1 Drugs (e.g., concomitant antiplatelet 
or NSAIDs) or alcohol excess/abuse
1 or 2
Sex category (i.e. female gender) 1
Maximum score 9 9
 INR, international normalized ratio; LV, left ventricular; MI, myocardial infarction; NSAIDs, non-
steroidal anti-inflammatory drugs; TIA/TE, transient ischemic attack/thromboembolism; PAD, 
peripheral artery disease
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older patients with recently diagnosed AF in the Quebec, Canada;41 
and 1.20 (95% CI 1.12–1.28) in the Danish nationwide cohort 
study.42  The age-dependancy of the female gender as a stroke risk 
factor was underscored throughout all studies, i.e., females with AF 
younger than 65 years were at low stroke risk and no antithrombotic 
prophylaxis was required.40-43
Finally, vascular disease was found to be an independent risk factor 
for stroke in AF (HR 1.14, 95% CI 1.06-1.23) in the Swedish Atrial 
Fibrillation cohort study, signiﬁcantly improving the predictive 
ability of CHADS2.38 Vascular disease remained significant even 
while peripheral artery disease (HR 1.22, 95% CI 1.12-1.32), 
myocardial infarction (HR 1.09, 95% CI 1.03-1.15), prior coronary 
artery bypass graft (HR 1.19, 95% CI 1.06-1.33) were considered 
separately.38 Predictive value of vascular disease was confirmed in 
other cohorts.39,40,44
Some confusion in the description of some risk factors, specifically 
heart failure and arterial hypertension, has been raised.  As heart 
failure is often defined as ‘history of heart failure’ irrespectively of 
functional class, left ventricular function, need for hospitalization 
was found to be not an independent risk factor for stroke both 
based on systematic literature reviews and analysis of contemporary 
data.26,38  In the CHA2DS2-VASc score, heart failure is used as ‘left 
ventricular moderate to severe systolic dysfunction or recent heart 
failure exacerbation that requires hospitalization’ (whether it is a 
heart failure with reduced or preserved ejection fraction).4  Questions 
still remain about impact of the heart failure with the preserved 
ejection fraction on stroke development in AF.  Indeed, this type 
of heart failure includes about half of heart failure patients and AF 
is particularly prevalent amongst them.45 In the Loire Valley Atrial 
Fibrillation Project, there were no differences in rates of stroke and/or 
thromboembolism between patients with heart failure with preserved 
and those with heart failure and reduced ejection fraction.46  Another 
study showed 3.3-fold higher rates (20.6% vs. 6.7%) of ischaemic 
stroke and 5.5-fold of deaths (27.2% vs. 2.0%) in patients with AF 
and heart failure with preserved ejection fraction compared to those 
with AF without heart failure at 3 years of follow-up.47
Hypertension in the CHA2DS2-VASc score is defined as a history 
of hypertension, assuming that prolonged history of hypertension 
even if well-controlled is associated with vascular changes, which 
predispose to stroke.8 Clearly, uncontrolled blood pressure also 
increases stroke risk in AF.
The CHA2DS2-VASc score was found to be superior to other 
stratification schemes in selection of the ‘truly low-risk’ in several 
cohorts.  Apart from Danish nationwide cohort and United Kingdom 
General Practice Research Databases33,34 the CHA2DS2-VASc 
score did the best in the Belgrade Atrial Fibrillation study which 
targeted ‘lone’ AF patients as it was the only stratification scheme, 
in accordance to which low risk (i.e. CHA2DS2-VASc score=0) was 
associated with the absence of stroke (OR 5.1, 95% CI 1.5-16.8).48 
This was consistent with a small study by Abu-Assi et al.49
Bleeding Risk Assessment In Atrial Fibrillation
Whilst prescribing oral anticoagulants for stroke prevention in AF 
patients, clinicians have to balance stroke prevention against the risk 
of bleeding, particularly major bleedings. Major bleeding is different 
from nonmajor by the following criteria: fatal bleeding, and/or 
symptomatic bleeding in a critical area or organ, such as intracranial, 
intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, 
score will be equal to 2, which will define patient’s risk as ‘moderate’ 
although systematic reviews of stroke risk factors all consider history 
of prior cerebral ischaemia as the most powerful predictor of stroke 
recurrence (relative risk 2.5, 95% CI 1.8 to 3.5).26 More recently, 
the low/moderate/high risk strata using the CHADS2 score was 
defined in the following way: CHADS2=0 – low risk, CHADS2=1 
– moderate risk, CHADS2≥2 – high risk.30  Recommendations 
on initiation of anticoagulation therapy in several guidelines were 
revised correspondingly with the CHADS2≥1 as indication for oral 
anticoagulants.31,32
Nonetheless, the low risk stratum according to the CHADS2 
score still appears have an adjusted stroke rate of 1.9 (95% CI 1.2-
3.0) per 100 patient-years.14 In the Danish nationwide cohort study 
(total number of participants 47576), there were 19444 patients at 
low stroke risk using the CHADS2 score (score=0).  They developed 
275 strokes during 1-year follow-up, with a stroke rate was 1.59 
(1.41-1.79).33  If these patients were substratified by the CHA2DS2-
VASc score (see later), the stroke rate ranged from 0.84 (95% CI 
0.65-1.08) if CHA2DS2-VASc=0 versus 3.2 (95% CI 1.60-6.40) if 
CHA2DS2-VASc=3.33  In the United Kingdom General Practice 
Research Database, which included 79844 patients with AF during 
approximately 4 years follow-up, the average annual incidence rate in 
the CHADS2=0 was lower (1.0 per 100 person-years), but still more 
than 2-times higher when compared with the CHA2DS2-VASc=0.34
The CHA2DS2-VASc ScoreThe CHA2DS2-VASc score was developed to refine stroke risk 
stratification of patients with particular emphasis on identifying those 
in the low risk category.30,35  CHA2DS2-VASc score consists of ‘major’ 
risk factors (prior stroke or TIA, or thromboembolism, and older age 
≥75 years) and ‘clinically relevant non-major’ risk factors (heart failure 
[moderate to severe left ventricular systolic dysfunction, deﬁned as 
left ventricular ejection fraction ≤40% or recent decompensated heart 
failure requiring hospitalization], hypertension, diabetes, female 
sex, age 65–74 years, and vascular disease (speciﬁcally, myocardial 
infarction, complex aortic plaque and peripheral artery disease).
Improvement of stratification has been achieved in part by adding 
‘non-CHADS2’: female gender, vascular disease, separation of age as 
a risk factor into two subcategories. The CHADS2 score has been 
frequently criticized because of not including these important stroke 
factors.36,37
Support for the ‘new’ risk factors was derived from the Swedish 
Atrial Fibrillation cohort study, which included 182 678 patients 
with AF and followed-up for about 1.4. years.38  The risk of stroke in 
this study was found to be increased from age ≥65 years, with even 
greater risk at age 75 years or older: hazard ratio (HR) 2.97 (95% 
CI 2.54-3.48) and HR 5.28 (95% CI 4.57-6.09), respectively, when 
compared with the ‘reference’ age <65 years.38 Consistent results were 
reported from the Taiwanese nationwide cohort study: odds ratios 
(OR) of 1.34 (95% CI 1.06-1.69) and 1.65 (95% CI 1.31-2.08) 
were seen for age 65-74 and ≥75 years categories, respectively.39  The 
stroke/thromboembolic event rate per 100 person-years in the Loire 
Valley Atrial Fibrillation Project was 0.23 (95% CI, 0.08-0.72) in 
patients <65 years old, 2.05 (95% CI 1.07-3.93) in those aged 65-74 
years, and 3.99 (95% CI, 2.63-6.06) if ≥75 years.40
Female gender is a moderate risk factor for stroke in AF overall, 
but there is an age dependency. For example, HRs were 1.17 (95% 
CI 1.11-1.22) in the Swedish Atrial Fibrillation cohort study38 
;1.14 (95% CI 1.07-1.22)  in the population-based cohort study of Ре
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or intramuscular with compartment syndrome, and/or bleeding 
causing a fall in hemoglobin level of 20 g/L or more, or leading to 
transfusion of two or more units of whole blood or red cells.50
The reported rate of intracranial haemorrhage, which is the most 
devastating example of bleeding event, has increased markedly with 
spreading use of anticoagulants in older adults often with AF as the 
only indication.51  A recent meta-analysis of data on major bleeding 
in oral anticoagulation found an overall incidence of 2.1 (ranged 0.9–
3.4) for the randomized clinical trials and 2.0 (ranged 0.2–7.6) per 
100 patient-years for observational studies.52
In line with stroke risk in AF bleeding risk in anticoagulation also 
is not homogeneous. Different bleeding risk stratification schemes to 
evaluate it were developed, however only three of them were derived 
and validated in AF populations.53
The HEMORR2HAGES score (hepatic or renal disease, ethanol 
abuse, malignancy, older [aged ≥75 years], reduced platelet count 
or function, rebleeding risk, hypertension [uncontrolled], anaemia, 
genetic factors [CYP2C9 single nucleotide polymorphism], excessive 
fall risk, and stroke) was derived based on known bleeding risk factors 
from the National Registry of Atrial Fibrillation.54 Prediction of 
bleeding events was improved with the use of HEMORR2HAGES 
score, but its application to everyday clinical practice was limited 
because of necessity of genetic testing. In addition, genetic 
polymorphisms other than CYP2C9 gene, are also involved in in 
warfarin metabolism have been shown, e.g., for example, VKORC1.55
The HAS-BLED score (hypertension, abnormal renal/liver 
function, previous stroke/TIA, bleeding history or predisposition, 
labile international normalized ratio, elderly [e.g. age ≥65, frailty, 
etc.], drugs/alcohol concomitantly)56  gained success as a very simple 
stratification scheme in comparison to the HEMORR2HAGES 
score performance, based on validations in various independent ‘real 
world’ cohorts.38,57  It was associated with improvement of bleeding 
risk classification when compared with variety of bleeding risk 
stratification schemes, including the new ATRIA score (see below) 
in the Loire Valley Atrial Fibrillation Project.58  Amongst major 
advantages of the HAS-BLED score its ability to predict intracranial 
haemorrhage, the high performance in both AF and non-AF 
populations, in patients taking warfarin or other anticoagulants, as 
well as for bridging therapy were highlighted.59-62
The ATRIA (anemia, severe renal disease [GFR<30 ml/min or 
dialysis-dependent], age≥75 years, previous bleed, hypertension) is 
the newest bleeding risk score propsed.63  The ATRIA bleeding score 
defines elderly patients as aged ≥75 years (versus ≥65 in the HAS-
BLED score) and hypertension is defined ‘history of hypertension’ 
versus ‘uncontrolled hypertension’ in the HAS-BLED score.63 
Thus, the predictive and discriminative ability ATRIA score was 
poorer when compared to HAS-BLED, including failure to predict 
intracranial haemorrhage.59,64
Current guidelines recommend to perform evaluation of bleeding 
risk in all patients with AF routinely but to focus on those with high 
bleeding risk (i.e. HAS-BLED score ≥3). This should be realized 
through regular follow-up and reduction of impact of potentially 
modifiable risk factors, e.g. achievement of blood pressure control, 
stable INR values, patients’ education to avoid alcohol intake and 
minimize use of aspirin or non-steroidal anti-inﬂammatory drugs. 
The benefits of anticoagulation clearly outweigh hazard of bleeding, 
furthermore, with higher bleeding risk even greater net clinical 
benefit might be expected.6,7  Indeed, anticoagulation therapy should 
not to be discontinued on the grounds of a high HAS-BLED score.4 
It should be noted that the labile INR criterion in HAS-BLED is 
only considered only in case of vitamin K antagonist (e.g. warfarin) 
use. Stability of INR is very important, and only if patient spends 
more than 70% of time within therapeutic range (TTR), the best 
effectiveness and safety profiles can be expected;  in contrast, low 
average TTR is associated with poor outcomes (stroke, bleeding 
mortality).65-68
Thus, efforts towards development of prediction tool for quality 
of INR control (as reflected by TTR) have been made. The SAMe-
TT2R2 score (female sex, age less than 60 years, medical history [2 
of the following: hypertension, diabetes, coronary artery disease/
myocardial infarction, peripheral artery disease, heart failure, 
previous stroke, pulmonary, hepatic or renal disease], treatment with 
interacting drugs [e.g. amiodarone], tobacco use (within 2 years), 
non-Caucasian race) was described from an analysis of the Atrial 
Fibrillation Follow-up Investigation of Rhythm Management 
(AFFIRM) trial in order to aid decision-making between vitamin 
K antagonists and novel oral anticoagulants by identifying those AF 
patients who would do well on VKA (SAMe-TT2R2 score 0-1), and 
those who less likely reach target TTR (SAMe-TT2R2 score ≥2).69,70
Integrated Stroke And Bleeding Risk Assessment
As many of the risk factors for stroke and bleeding in AF are 
overlapped is it possible to use one stratification scheme to get 
simultaneously individuals’ stroke and bleeding risk?  This was tested 
in two ways.  First, the predictive ability for major bleedings was 
assessed using the stroke risk stratification scores, that is, CHADS2 
and CHA2DS2-VASc.  For example, in the AMADEUS (evaluating 
the use of sr34006 compared to warfarin or acenocoumarol in 
patients with atrial fibrillation) trial incidence of bleeding was 
found to rise with increasing of either HAS-BLED, CHADS2, or 
CHA2DS2-VASc scores, but statistical significance was achieved only 
for the HAS-BLED score.  Also, only HAS-BLED demonstrated 
significant discriminatory performance and net reclassification 
improvement when compared with the CHADS2 and CHA2DS2-
VASc as well.71 Thus, stroke risk stratification schemes should not 
be applied for bleeding risk assessment instead of the HAS-BLED 
score.
Second, several composite scores for stroke and bleeding prediction 
have been developed.72,73  For example, evaluation of composite end 
point ‘stroke/thromboembolism or major bleeding’ was predicted by 
age, previous stroke/TIA, aspirin use, and time in therapeutic range. 
Predictors for another composite end point ‘stroke, systemic or venous 
embolism, myocardial infarction, cardiovascular death, or major 
bleeding’ were the same but included left ventricular dysfunction as 
well.72  Generally, regression models are likely to give more faithful 
conclusions on patient’s stroke or bleeding risk as they include 
appropriate regression coefficients which characterize the real impact 
of risk factors on the studied outcome instead of assumption of equal 
weight (1 or 2 points) for the range of stroke predictors.  However, 
both models actually allowed comparative discriminative ability in 
comparison to the CHA2DS2-VASc and HAS-BLED scores, but did 
not outperform them.72  Thus, taking into account relative complexity 
of calculations with composite scores, the ‘traditional’ stroke and 
bleeding risk scores which are currently in use are more attractive in 
the aspect of usability, detailed assessment, individualized balancing 
of risks, and right decision making.Ре
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status, systolic blood pressure, ratio of total serum cholesterol to high 
density lipoprotein cholesterol concentrations, body mass index, 
family history of coronary heart disease in first degree relative under 
60 years, Townsend deprivation score, treated hypertension, type 1 
and type 2 diabetes, renal disease, rheumatoid arthritis, coronary 
heart disease, congestive heart failure, valvular heart disease, and 
AF. Incorporation of AF as a separate risk factor means that the 
QStroke score also can be used in non-AF patients.  Unfortunately, 
the QStroke score did not outperform both the CHADS2 and the 
CHA2DS2-VASc score in patients without a prior stroke.85
Also, future improvement of stroke risk stratiﬁcation can be 
achieved by inclusion of biomarkers to complement clinical risk 
factors.  Echocardiographic parameters (presence of spontaneous 
echocontrast, low left atrial appendage velocities, left atrial 
appendage thrombus, and complex aortic plaque on the descending 
aorta);86,87 blood biomarkers of prothrombotic or hypercoagulable 
state (von Willebrand factor, D-dimer)88-91; left-ventricular overload 
(brain natriuretic peptide, galectin-3);92,93 renal function (creatinine 
clearance, estimated glomerular filtration rate, proteinuria);94-96 
detailed cerebral imaging with computer tomography or magnetic 
resonance imaging (presence of small-vessel disease)3 were shown to 
have prognostic implications in AF patients.
Of these, the impact of chronic kidney disease (CKD) in stroke 
stratification schemes is of particular importance as CKD is 
associated strongly with increased cardiovascular morbidity and 
mortality.  The range of cardiovascular disorders associated with 
CKD is wide, with arterial stiffening causing heart failure, stroke, 
and arrhythmic sudden death and premature atherosclerosis causing 
vascular occlusive events.97  The prevalence of AF was recognized to 
be higher in CKD and prognosis is known to be negative regarding 
both thromboembolic and bleeding risk in comparison to general 
population.97  At the same time, there is relatively poor evidence for 
anticoagulation in the given cohort of patients as CKD was used as 
exclusion criterion in majority of studies (particularly if eGFR<30 
ml/min/1.73 m2).
The R2CHADS2 score was derived from the ROCKET AF 
(Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition 
Compared with Vitamin K Antagonism for Prevention of Stroke and 
Embolism Trial in Atrial Fibrillation) cohort.  The score incorporated 
the components of the CHADS2 score and also awarded 2 points 
for creatinine clearance <60 mL/min.98  When validated in the 
ATRIA study, improvement of net reclassification index by 17.4% 
(95% CI 12.1-22.5) was seen, relative to CHADS2.98 However, some 
methodological issues were underscored and discussed that might 
limit spread of the R2CHADS2 score in clinical practice.99
Conclusions:
Numerous risk stratifications schemes for stroke and bleeding 
prediction highlight the fact, that none is perfect and further 
research is needed to improve the individuals’ risk assessment. 
Given the global burden associated with AF and its complication 
such as stroke, new treatment options could have a major impact on 
reducing this healthcare burden associated with AF-related stroke, as 
recently shown for Europe and China.100-102  For now, the CHA2DS2-
VASc and the HAS-BLED scores are currently superior to other 
prognostic tools in guiding anticoagulation in AF patients without 
losing simplicity and practicality for everyday use.  With stroke 
risk, the focus now is the initial indentification of ‘low risk’ patients 
Further Directions To Improve Risk Scores: Are More ‘Non-
Traditional’ Clinical Factors And Biomarkers The Answer?
Clearly, there are a lot of clinical risk factors for thromboembolism 
and bleeding, which were not included into the current risk 
stratification schemes but had potential to improve their performance.
For example, a history of both arterial (HR 1.39, 95% CI 1.08-
1.79) and venous (HR 1.26, 95% CI 1.02-1.54) retinal occlusions 
was found to be associated with an increased risk of stroke/
thromboembolism/TIA in patients with non-valvular AF.  As 
cerebral and retinal circulation are adjacent, it was suggested 
that retinal vascular occlusion could be considered as a previous 
thromboembolic event when evaluating stroke risk.74 Despite that, 
AF in eye ischaemic events is much less prevalent than in cerebral 
ischaemia; indeed, the probability to diagnose AF in patient with 
stroke is about 3.6-fold higher than in patient with retinal artery 
occlusion.  Hence, counterpoint view is that stroke and retinal 
thrombosis may represent pathophysiologically distinct patterns of 
vascular disease.75
Obesity apart from being a risk factor for development of new-
onset AF76,77 and stroke risk factor in the general population,78 does 
have an independent predictive role for stroke development in patients 
with AF.79  In the prospective Danish Diet, Cancer and Health study 
there was a 31% and 36% increase in risk of the composite end point 
of ‘ischaemic stroke, thromboembolism, or death’ in overweight and 
obese patients, respectively, even after adjustment for CHA2DS2-
VASc score.79
Data derived from the same cohort was indicative for relation of 
alcohol intake.  Men with an intake of >27 drinks/week were more 
prone to develop thromboembolism or death (HR 1.33, 95% CI 
1.08-1.63) compared to men with an intake of <14 drinks/week. 
Women with an intake of >20 drinks/week also had a higher risk 
(HR 1.23, 95% CI 0.78-1.96) than women in the low intake category 
(adjusted for oral anticoagulation and CHA2DS2-VASc scores).80 
Heavy smoking, was found to be independently associated with a 
higher risk of thromboembolism or death as well (HR 3.64 [95% 
CI 1.88-7.07] for females, and HR 2.17 [95% CI 1.59-2.95] for 
males).81
Ethnic differences are important for stroke prediction. Specifically, 
Asians represents large population with overall higher burden of 
AF than in Western countries.82,83  Despite stroke risk factors being 
common for both populations, oral anticoagulation is underused and 
decision-making does not correspond to individual risk, assessed 
via modern stratification schemes.  Based on data from the China 
National Stroke Registry, only about 15% of moderate and high risk 
patients according to the CHADS2 score were taking warfarin.84 
Moreover, stroke scores were derived and validated in predominantly 
Caucasians and, hence, may have lower prediction strength when 
applied to population in the Far Eastern countries. For example, 
in the nationwide database of patients with nonvalvular AF from 
Taiwan, CHADS2 and CHA2DS2-VASc scores had only modest 
predictive ability.39
The role of ethnicity as well as some aforementioned risk factors 
(e.g., smoking, obesity) was advocated in a new QStroke score, that 
was proposed based on England and Wales general practice data. The 
QStroke score was validated for AF patients without a prior stroke 
only.  Besides 9 categories that included self-assigned ethnicity and 
a wide range of other risk factors that included age, sex, smoking Ре
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